Genmab — Januar 2022
-
Genmab and Synaffix Enter into License Agreement for ADC Technology https://www.proinvestor.com/investornyt/758658/genmab-and-synaffix-enter-into-license-agreement-for-adc-technology
-
Synaffix even partnered with ADCT ...
-
https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies
-
Det er ikke helt klart om de $415 mio er per target/antistof, eller om det er den øvre grænse for max x projekter
-
ja men vi ved ikke hvor mange targetes der er tale om. Men egentligt kunne man (læs mig selv) også sige sig selv at der er tale om flere aftaler til det beløb. For der bliver ikke indgået SÅ store deals på enkelt target/antistof der først nu skal startes op. Altså bliver det ikke mere earlystage end det her
-
Så vi taler nok 3-5 targets i alt
-
Genmab indgår lincensaftale med Synaffix om ADC-teknologi - NY https://www.proinvestor.com/investornyt/758686/genmab-indgar-lincensaftale-med-synaffix-om-adc-teknologi-ny
-
Sukker jeg tror det er flere targets. De betaler ikke plus $200 mio for en forsknings aftale. Det var sådan en aftale JnJ betale $20 mio per target på den gamle aftale
-
Bemærk genmab står for alle udgifter. Det koster på royaltieses og milstones
ok
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind